智通财经APP获悉，天星医疗(01609)盘中涨超12%，截至发稿，涨10.38%，报150港元，成交额1324.27万港元。
消息面上，近日，天星医疗自主研发的集成一体无线缆手持刨削系统（型号：WP-100）成功入选《北京市2026年第二批首台(套)重大技术装备目录》，这是继“碳纤维复合聚醚醚酮带线锚钉”获得首台（套）认证后，再次喜获医疗健康领域首台（套）重大技术装备认证。这标志着天星医疗在运动医学领域实现了又一重大突破，彰显了公司在自主创新方面的强大实力。
公开资料显示，天星医疗是中国领先的运动医学整体解决方案提供商，专注于运动医学植入物、手术设备及相关耗材的研发、生产与商业化。公司产品主要用于肩、膝、髋、踝等关节软组织损伤的修复与重建，也提供运动康复及预防的全方位解决方案。根据灼识咨询数据，按2024年销售收入计，天星医疗为中国第四大、国产第一大运动医学植入物及器械供应商，市场份额6.5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.